NCT05312879

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2022-03-30Est. Completion: 2028-06-02

Enrollment target: 466 participants

Locations

Alabama Kidney Research, Alabaster, Alabama, United States
EmVenio Research - Mobile Unit - Birmingham, Birmingham, Alabama, United States
Cardiology, P.C., Birmingham, Alabama, United States
Children's Hospital of Alabama, Birmingham, Alabama, United States
The Kirklin Clinic - Nephrology, Birmingham, Alabama, United States
Nephrology Associates, Fairhope, Alabama, United States
Heart Center Research LLC, Huntsville, Alabama, United States
Nephrology Consultants, LLC, Huntsville, Alabama, United States
Renal Associates of Alabama, LLC, Montgomery, Alabama, United States
Arizona Kidney Disease and Hypertension Center - Banner Desert Office, Mesa, Arizona, United States
Arizona Kidney Disease and Hypertension Center - Thomas Office, Phoenix, Arizona, United States
Phoenix Children's Hospital, Inc. - Nephrology, Phoenix, Arizona, United States
CHI St. Vincent Heart Clinic Arkansas- Cardiology and Medicine Clinic - Little Rock, Little Rock, Arkansas, United States
UAMS Medical Center - Pulmonology, Little Rock, Arkansas, United States
The Medical Research Group - Saint Agnes Medical Center, Fresno, California, United States

Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFS…

Huntsville, United StatesEst. completion Jan 20, 2028

IgA NephropathyFocal Segmental GlomerulosclerosisAlport SyndromeDiabetic Kidney DiseaseDiabetic Nephropathy Type 2Immunoglobulin A Nephropathy

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients …

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.